2023
DOI: 10.1016/j.nicl.2023.103339
|View full text |Cite
|
Sign up to set email alerts
|

Dynamics of progressive degeneration of major spinal pathways following spinal cord injury: A longitudinal study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 53 publications
0
2
0
Order By: Relevance
“…[36][37][38] One substantial benefit of the tMPPCA denoising technique is that it provides its advantages not only to future studies but also retrospectively increases spatial and temporal SNR of already acquired and published data. This might allow to better delineate small anatomical brain structures 50,51 or detect the dynamics of microstructural changes 52,53 with increased sensitivity. In future MPM studies, tMPPCA denoising can be utilized to considerably reduce scan time for clinical applications or to push the resolution of cutting-edge MPM protocols from the upper to the lower limit of the mesoscopic scale.…”
Section: Discussionmentioning
confidence: 99%
“…[36][37][38] One substantial benefit of the tMPPCA denoising technique is that it provides its advantages not only to future studies but also retrospectively increases spatial and temporal SNR of already acquired and published data. This might allow to better delineate small anatomical brain structures 50,51 or detect the dynamics of microstructural changes 52,53 with increased sensitivity. In future MPM studies, tMPPCA denoising can be utilized to considerably reduce scan time for clinical applications or to push the resolution of cutting-edge MPM protocols from the upper to the lower limit of the mesoscopic scale.…”
Section: Discussionmentioning
confidence: 99%
“…The validity and applicability of synT 1 -w images in clinical studies was assessed by directly comparing CSA measurements derived from MPRAGE with those derived from synT 1 -w in a longitudinal study that involved healthy participants and SCI patients ( Azzarito et al, 2020 ;Freund et al, 2013b ;Grabher et al, 2015 ;Schading et al, 2023 ;Seif et al, 2018aSeif et al, , 2018bZiegler et al, 2018 ). As the CSA has been proposed as a marker for neurodegeneration in clinical trials ( Casserly et al, 2018 ;Freund et al, 2013a ;Kearney et al, 2015 ;Schmierer and Miquel, 2018 ;Seif et al, 2019 ), optimizing acquisition time of study protocols can help to improve patient comfort, data quality and scan costs.…”
Section: Agreement Between Csa From Mprage and Synt 1 -Wmentioning
confidence: 99%